Pharmaceutical companies Moderna and Merck have announced preliminary successes in the Phase 3 trial of their personalised melanoma vaccine
In a press release, the pharmaceutical companies Moderna and Merck have announced the results of their ongoing Phase 3 INTerpath-001 clinical trial, which is evaluating an mRNA vaccine (intismeran) in combination with pembrolizumab in patients with completely resected Stage IIB–IV melanoma. There is as yet no scientific publication containing data on improved survival or a reduction in recurrence.
0